You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》藥明生物(02269.HK)分拆藥明合聯通過上市聆訊
藥明生物(02269.HK)分拆藥明合聯生物技術上市已通過聯交所上市聆訊,由摩根士丹利、高盛及摩根大通擔任聯席保薦人。 最新初步招股資料顯示,藥明合聯生物是專注於全球抗體藥物偶聯物(ADC)及更廣泛生物偶聯藥物市場的領先合同研究、開發及製造組織(CRDMO),截至今年6月30日止共有110個正在進行中的整體項目,當中分別有67個正在進行的臨牀前生物偶聯藥物項目及43個正在進行的IND後生物偶聯藥物項目;並在全球幫助客戶提交47款ADC候選藥物的IND申請。 截至6月底止上半年,該公司錄得收入9.93億元人民幣,按年增加逾兩倍,期內利潤則增長80%至1.77億元人民幣。非國際財務報告準則下經調整淨利潤爲2.16億元人民幣,按年升98.8%。 於上市前,藥明生物於藥明合聯的持股爲60%,而藥明康德(02359.HK)則透過旗下合全藥業持有餘下40%股份。 藥明合聯計劃在上市後,運用集資所得於新加坡興建生產設施及擴大在中國的抗體中間體產能,以進一步擴大生產能力,並有計劃選擇性地尋求戰略聯盟、投資及收購機會,以擴大技術平臺及服務類型。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account